文献速递造血干细胞移植与细胞治疗

移植前靶向TNFRSF25与CD25刺激受者调节性T细胞在靶组织扩增并改善造血干细胞移植后移植物抗宿主病

Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.
PubMed 文献 · Blood · 2025-01-01

该研究在小鼠同种异体造血干细胞移植前,用TL1A-Ig融合蛋白和低剂量IL-2分别靶向TNFRSF25与高亲和力IL-2受体,诱导受者调节性T细胞扩增并持续至移植后1至2周,减轻移植物抗宿主病并改善移植结局,同时保留移植物抗白血病效应。

要点

  • 移植前靶向TNFRSF25与CD25可诱导受者Treg扩增并持续至移植后1至2周。
  • 该预处理减轻GVHD并改善移植结局,同时在结肠、肝脏和眼形成抑制性组织环境。
  • 该策略在受者接受供者异体反应性T细胞前即建立抑制性靶组织环境,并保留移植物抗白血病效应。

核心结论

  • 移植前用TL1A-Ig融合蛋白和低剂量IL-2靶向TNFRSF25与CD25诱导受者Treg扩增,可减轻GVHD并改善移植结局;作者认为通过体内受者Treg扩增可能绕开体外大量制备Treg的需求,为改善aHSCT结局提供转化途径。

研究设计与样本

  • 在异基因造血干细胞移植(aHSCT)前,用TL1A-免疫球蛋白(TL1A-Ig)融合蛋白和低剂量IL-2分别靶向TNFRSF25与高亲和力IL-2受体,对受者小鼠进行预处理。

主要发现

  • 预处理诱导的Treg扩增在HSCT后持续1至2周,并伴随稳定且活跃的Treg频率增加。
  • 在结肠、肝脏和眼形成抑制性组织环境。
  • 预处理支持上皮细胞功能/完整性、维持微生物组多样性(包括减少致病菌过度生长、促进产丁酸菌),同时维持专性/兼性厌氧菌的生理水平。
  • 使用1-磷酸鞘氨醇受体激动剂将T细胞滞留于淋巴组织后发现,组织Treg频率增加包括驻留的CD69+CD103+FoxP3+肝脏Treg。
  • 与输注供者Treg不同,该策略在受者接受供者异体反应性T细胞前即形成抑制性靶组织环境,并成功保留移植物抗白血病效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current approach to minimize transplant-associated complications, including graft-versus-host disease (GVHD) includes long-term pharmacological immune suppression frequently accompanied by unwanted side effects. Advances in targeted immunotherapies regulating alloantigen responses in the recipient continue to reduce the need for pan-immunosuppression. Here, in vivo targeting of the tumor necrosis factor superfamily receptor TNFRSF25 (also known as DR3) and the high-affinity interleukin-2 (IL-2) receptor with a TL1A-immunoglobulin (TL1A-Ig) fusion protein and low-dose IL-2, respectively, was used to pretreat recipient mice before allogeneic hematopoietic stem cell transplantation (aHSCT). Pretreatment induced regulatory T cell (Treg) expansion persisting 1 to 2 weeks after HSCT, leading to diminished GVHD and improved transplant outcomes. Expansion was accompanied by an increase in the frequency of stable and active Tregs, creating a suppressive tissue environment in the colon, liver, and eye. Importantly, pretreatment supported epithelial cell function/integrity, a diverse microbiome including reduction of pathologic bacteria outgrowth, and promotion of butyrate producing bacteria, while maintaining physiologic levels of obligate/facultative anaerobes. Notably, using a sphingosine 1-phosphate receptor agonist to sequester T cells in lymphoid tissues, it was found that the increased tissue Treg frequency included resident CD69+CD103+FoxP3+ hepatic Tregs. In contrast to infusion of donor Tregs, the strategy developed here resulted in the presence of immunosuppressive target tissue environments in the recipient before the receipt of donor allogeneic-reactive T cells and successful perseveration of graft-versus-leukemia responses. We posit strategies that circumvent the need of producing large numbers of ex vivo manipulated Tregs may be accomplished through in vivo recipient Treg expansion, providing translational approaches to improve aHSCT outcomes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. McManus D, Copsel SN, Pfeiffer BJ, et al. Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT. Blood. 2025. PMID: 40749165. doi:10.1182/blood.2025028418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。